In the Media

Viewing records where tag name contains "media" View All

Australian biotech back on the international stage

Jun 7th, 2022

Starpharma's CEO Dr Jackie Fairley was interviewed by ausbiz during Starpharma's visit to the United States for the American Society of Clinical Oncology (ASCO) Annual Meeting as well as partnering discussions. 

Read More

Starpharma one of a number of Australian companies in the US for major oncology conference

Jun 7th, 2022

"For the first time in more than two years, a number of Australian biotechnology companies are in the US for one of the world's most important oncology events - the global conference of the American Society of Clinical Oncology (ASCO)." Starpharma featured in Biotech Dispatch during its visit to the United States for ASCO. 

Read More

Starpharma's nasal spray effective against influenza A & B virus

May 23rd, 2022

BioSpectrum Asia features Viraleze, following Starpharma's announcement about SPL7013's virucidal activity in influenza A and B. 

Read More

Starpharma’s (ASX:SPL) antiviral agent fights back against against influenza virus

May 18th, 2022

The Market Herald reports on Starpharma’s SPL7013 agent, which achieved up to 99.7 per cent reduction in viral activity against two types of influenzas virus.

Read More

Starpharma (ASX:SPL) to relaunch VIRALEZE treatment in UK

Apr 1st, 2022

The Market Herald features Starpharma following its latest announcement related to the relaunch of VIRALEZE™ in the UK.

Read More

Active agent in Australian-developed nasal spray highly active against 'Omicron'

Mar 2nd, 2022

Australian biotechnology and life sciences media platform, BiotechDispatch, featured the news of Starpharma's latest announcement regarding SPL7013's virucidal activity against Omicron.

Read More

Starpharma’s (ASX:SPL) nasal spray outperforms competitors against Omicron variant

Mar 1st, 2022

"Starpharma’s (SPL) antiviral nasal spray has achieved a greater than 99.5 per cent reduction of virus infectivity against the Omicron variant of SARS-CoV-2." The Market Herald reports on Starpharma, following the company's latest announcement. 

Read More

Starpharma (ASX:SPL) pens distribution deal in Saudi Arabia

Feb 3rd, 2022

The Market Herald reports on Starpharma's new partnership with Etqan & Nazahah for the sales and distribution of VIRALEZE™ in Saudi Arabia. 

Read More

Starpharma’s (ASX:SPL) December quarter boosted by VIRALEZE success

Jan 28th, 2022

The Market Herald reports on Starpharma, following the release of the company's Quarterly Cashflow and Activities Report.

Read More

Australian homegrown COVID-19 pipeline shows signs of maturity

Jan 27th, 2022

Starpharma's CEO Dr Jackie Fairley was interviewed by BioWorld about the company's antiviral nasal spray VIRALEZE™.

Read More

Starpharma announces early orders following Vietnam distribution agreement

Dec 14th, 2021

BiotechDispatch report on Starpharma's latest announcement related to the launch of VIRALEZE™ in Vietnam. 

Read More

Starpharma (ASX:SPL) tables $2m in Vietnam VIRALEZE orders

Dec 13th, 2021

"Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totaling more than $2 million for Vietnam", as reported in The Market Herald.

Read More

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

Nov 30th, 2021

Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.

Read More

Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov 27th, 2021

Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha. 

Read More

Starpharma Releases Positive DEP® Phase 2 Interim Results In Prostate Cancer

Nov 27th, 2021

British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.

Read More

Starpharma Announces Encouraging Interim Results for Prostate Cancer Drug

Nov 27th, 2021

Gene Online reports on the news of Starpharma's latest announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel. 

Read More

Starpharma (ASX:SPL) continues VIRALEZE success in December quarter

Oct 29th, 2021

"Starpharma (SPL) has released its September quarterly report, with the quarter again highlighted by the continued success of VIRALEZE," as reported by The Market Herald. 

Read More

Starpharma signs distribution agreement for antiviral in Vietnam

Oct 26th, 2021

News of Starpharma signing an initial supply contract for VIRALEZE™ in Vietnam featured in BiotechDispatch. Read the article here

Read More

Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Oct 26th, 2021

The Market Herald features news of Starpharma's latest supply arrangement for VIRALEZE™ in Vietnam.

Read More

Nanotechnology Offers New Ways To Fight An Endless Pandemic

Oct 18th, 2021

Starpharma's VIRALEZE™ antiviral nasal spray was featured in Report Wire.

Read More